Anti depression drug developer Bionomics completes equity raising
Bionomics has successfully completed an over-subscribed equity raising from current shareholders, raising $2.2 million before costs. The raising will accelerate the commercialisation of the company’s drug candidate, BNC210 for the treatment of post traumatic stress disorder. The company is also developing drugs for the treatment of pain, cognition and epilepsy.
Aurora Labs progresses 3D metal printer development
Metal 3D metal printer developer Aurora Labs has reported it has successfully completed the Phase one testing phase in a 12-month process of developing its RMP-1 additive manufacturing printer. The test showed rapid manufacturing capability of parts (pictured) with a density greater than 99 per cent across full laser power range. The model should be completed by the end of 2010-2021.
Picture: Aurora Labs
Subscribe to our free @AuManufacturing newsletter here.